A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.

Brief description of study

You can participate in this study if you are diagnosed with stage 3 or stage 4 skin melanoma. The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (the activity of a drug in the body), and antitumor activity of KIN-2787 in participants with Rapidly accelerated fibrosarcoma, homolog B (BRAF) and/or Neuroblastoma- Rat sarcoma viral oncogene homolog (NRAS) mutation-positive solid tumors. Dose escalation will continue until the highest planned dose level is determined to be safe and tolerable. Dose expansion will assess preliminary evidence of the anti-cancer activity of KIN-2787 in participants with advanced or metastatic solid cancers. The study will be conducted in 2 parts. Part A comprises 2 components: 1) Dose Escalation: KIN-2787 Monotherapy (Part A1); and 2) Dose Escalation: KIN-2787 + Binimetinib Combination.(Part A2). Part B Dose Expansion will assess preliminary evidence of the anti-cancer activity of KIN-2787 in participants with advanced or metastatic solid cancers.


Clinical Study Identifier: s22-00213
ClinicalTrials.gov Identifier: NCT04913285


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.